Decentralized Clinical Trials Among Topics Slated For CDER Guidance In 2020

 
• By Brenda Sandburg

US FDA's to-do list also includes guidances on development of non-opioid analgesics and cannabis compounds, evaluation of generic therapeutic equivalence, and pediatric product development.

Vintage hourglass on yellow background with to do list in 2020 text.
FDA issues list of guidances it plans to publish this year

More from Generics

More from Biosimilars & Generics